ConductScience.org, home
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
API referenceFor AI assistants

Trial · NCT03466411

Participant flow52

How many started, completed or left each group, period by period.

1 to 20 of 52

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDGALAXI 1 (Group 1) Guselkumab 1200 mg IV q4w Followed by 200 mg SC q4w73
Overall StudySTARTEDGALAXI 1 (Group 2) Guselkumab 600 mg IV q4w Followed by 200 mg SC q4w73
Overall StudySTARTEDGALAXI 1 (Group 3) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w73
Overall StudySTARTEDGALAXI 1 (Group 4) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w71
Overall StudySTARTEDGALAXI 1 (Group 5) Placebo q4w Followed by Placebo q4w or Ustekinumab 6mg/kg IV Then 90mg SC q8w70
Overall StudySTARTEDGALAXI 2 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w148
Overall StudySTARTEDGALAXI 2 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w149
Overall StudySTARTEDGALAXI 2 (Group 3) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w150
Overall StudySTARTEDGALAXI 2 (Group 4) Placebo q4w Followed by Placebo q4w or Ustekinumab 6 mg/kg IV Then 90 mg SC q8w77
Overall StudySTARTEDGALAXI 3 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w151
Overall StudySTARTEDGALAXI 3 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w148
Overall StudySTARTEDGALAXI 3 (Group 3) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w150
Overall StudySTARTEDGALAXI 3 (Group 4) Placebo q4w Followed by Placebo q4w or Ustekinumab 6 mg/kg IV Then 90 mg SC q8w76
Overall StudyParticipants Who Did Not Achieve CR at Week 12 and Crossed Over to UstekinumabGALAXI 1 (Group 1) Guselkumab 1200 mg IV q4w Followed by 200 mg SC q4w0
Overall StudyParticipants Who Did Not Achieve CR at Week 12 and Crossed Over to UstekinumabGALAXI 1 (Group 2) Guselkumab 600 mg IV q4w Followed by 200 mg SC q4w0
Overall StudyParticipants Who Did Not Achieve CR at Week 12 and Crossed Over to UstekinumabGALAXI 1 (Group 3) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w0
Overall StudyParticipants Who Did Not Achieve CR at Week 12 and Crossed Over to UstekinumabGALAXI 1 (Group 4) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w0
Overall StudyParticipants Who Did Not Achieve CR at Week 12 and Crossed Over to UstekinumabGALAXI 1 (Group 5) Placebo q4w Followed by Placebo q4w or Ustekinumab 6mg/kg IV Then 90mg SC q8w43
Overall StudyParticipants Who Did Not Achieve CR at Week 12 and Crossed Over to UstekinumabGALAXI 2 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w0
Overall StudyParticipants Who Did Not Achieve CR at Week 12 and Crossed Over to UstekinumabGALAXI 2 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03466411/flow

API referenceFor AI assistants